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Cytokines are the soluble messengers that immune cells produce to
either attack an invading organism or to talk to other types of
immune cells. They form part of the complex pattern of the
immune response, which can assist the development of cancer as
well as to eliminate it. In the foreword of this book, Glenn Dranoff
draws attention to the fact that the cytokines which are involved in
the chronic inflammatory pathways that are often associated with
cancer development (citing Hal Dvorak’s concept of cancer as a
wound that does not heal) may, while trying to effect the tissue
repair, perhaps unintentionally promote, tumour cell growth,
attenuate apoptosis and facilitate angiogenesis invasion and
metastases. Whereas cytokines are actively involved in this process
they have also been singled out for use as possible treatments.
Interferon and interleukin-2 are well-known examples of cytokines
that have been approved for cancer treatments and one of these
cytokines known as tumour necrosis factor-a (TNFa) exemplifies
the paradox that it was identified as a ‘tumour necrosis factor’ in
mice (and is still given to patients to kill tumours, such as in limb
perfusion) for melanoma and sarcoma, yet when chronically
produced by nearly all the cells of the immune system it can cause
the proliferation, invasion and metastases of tumour cells, hence
inhibiting it is also a rational target.
The book sets out to examine the role of cytokines in the
development of cancer and the first section focuses specifically on
chronic infectious diseases and the cytokines they produce and the
formation of cancer with specific chapters on Helicobacter pylori
and gastric cancer, HTLV-1 and the adult T-cell leukaemic
lymphoma syndrome, the herpes viruses and the association of
EBV with diffusely different tumours from Burkett’s lymphoma to
nasopharyngeal carcinoma. The fact that this is a common virus
and the tumours relatively uncommon means that there is a very
complicated interaction with the environment and the immune
system and this group of viruses are of particular interest as they
encode cytokine homologues, IL-10 in the case of EBV and
interleukin-6 and the viral interferon regulatory factors in the case
of human herpes virus type 8 (which causes Kaposi’s sarcoma).
The book then goes on to explore the possible similarities between
the chronic infectious state and non-infectious, pre-cancer
conditions associated with cancers and the role of cytokines, and
the first one being the paradox of the TNFa is reviewed in detail.
Drugs targeting TNFa are already making a big clinical impact,
such as the thalidomide family with analogues such as lenalido-
mide already being approved for use in myelodysplastic syndrome
and myeloma. Both thalidomide and lenalidomide were selected
purely for the ability to inhibit the TNF pathway but it is now
accepted that they are active in a number of pathways, including
antiangiogenic and anti-inflammatory ones. The chapter describes
the development of infliximab, a monoclonal antibody, which is
being trialled as an anticancer agent following its very successful
use in treating debilitating inflammatory disorders, such as
rheumatoid arthritis and Crohn’s disease.
The link between infectious agents, cytokines and cancer, as well
as the paradoxical actions of certain cytokines makes an excellent
introduction to what is a very comprehensive reference book.
There are major chapters on transforming growth factor-b, the
interleukin-1 family, the interleukin-4/13 family, interleukin-6 and
interleukin-10. All these chapters explore in depth the relationship
of these cytokines with cancer. In the case of interleukin-6, there is
a particular focus on Castleman’s disease. Then follows chapters
on the role of cytokines in multiple myeloma and the therapeutic
implications followed by two chapters on experimental cytokine
models and the genesis of cancer as well as the implications for
cancer prevention. The third section of the book focuses on
cytokines and the tumour stroma and their role in angiogenesis
and tumour progression, with one chapter focussing on the
biology of cancer, cachexia and the role of TNF a in it. The fourth
and final section of the book is devoted to cytokines and the
treatment of cancer with the cytokines not previously reviewed in
depth, currently in clinical use (or are in the development phase),
such as interleukin-2, the interferons and interleukin-12, which are
covered in separate chapters. Indeed, this last section should be
compulsive reading for all cancer physicians. In addition to the
good in-depth reviews of the clinically available cytokines already
mentioned, there are some very useful, practical chapters and in
particular, the one on combination cytokine therapy. An in-depth
knowledge of the role of all the various cytokines strongly suggests
that the combinations should be synergistic and this field is
reviewed in depth. Indeed, it is surprising how many combinations
have already been tried and reported in the clinic, not only are
there many doublet combinations but also triplet ones involving
the interferons, IL-2 and GMCSF. There is far too much
information to pre ´cis here but the field is plagued with doubts
about the correct doses to use and the optimal sequences to give
the cytokines. Logical sequences give the desired predicted result
such as when IL-2 and IL-12 are given, there is enhanced g
interferon and NK activity. However, although dramatic clinical
responses are seen, one cannot avoid the conclusion that these
responses occur no more frequently than would be expected with
either cytokine alone. Nevertheless, it is possible that the dosing
and sequencing of these combinations are crucial and that some of
the doses used, with significant side effects when they are too high,
may prevent the ability of any potential synergy to occur. Indeed, it
is hard to believe that very high doses of single cytokines, causing
significant systemic toxicity can act independently alone but are
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induced by injecting a highly infectious, dangerous agent and this
of course brings Cooley’s toxins to mind!
The final chapters deal with the potential of using fusion
proteins to target cytokine administration as well as the use of
cytokine-transfected cells as vaccines. The use of cytokines to
boost immune responses to non-transfected vaccines is a minor
omission here. There is a review of cytokines used in support of
care, which most clinicians will be familiar with, such as
erythropoietin, GCSF, etc., and a separate chapter exploring the
potential of anticytokine therapy based on inhibiting interleukin-1
and TNF. Interestingly, they do not mention IL-6, which is
currently being developed as a target by Centocor for a number of
conditions associated with a high IL-6 level.
In conclusion, this is a fascinating, comprehensive book on
cytokines in cancer, both as causative agents and potential
treatments. I was interested to hear a recent postgraduate entry
student complain to me that the most disappointing thing about
her course was the virtual absence of immunology and immuno-
therapy in it when it was clearly going to be the treatment of the
future! As her experience is not unique in the UK, I can only
recommend that in order to help this deficit that this book should
be one of the several in this field that should be compulsive
reading for clinicians, students and their non-clinical teachers
alike!
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